MapLight Therapeutics files for 14.75M share IPO at $17/sh

MapLight Therapeutics Inc. filed a registration statement with the Securities and Exchange Commission for an initial public offering of 14,750,000 shares at $17.00 per share. The clinical-stage biopharmaceutical company, which focuses on central nervous system disorders, applied to list on the Nasdaq Global Market under ticker NASDAQ: MPLT.

The company granted underwriters a 30-day option to purchase an additional 2,212,500 shares. MapLight also announced a concurrent private placement of 476,707 shares to Goldman Sachs affiliates at the public offering price, though this sale would not be registered under the Securities Act of 1933.

The registration statement includes specific language under Rule 473(b) that would make it automatically effective 20 calendar days after filing, or October 26, 2025, under Section 8(a) of the Securities Act. MapLight expects to complete pricing on or after that date, but stated it will re-evaluate using Section 8(a) if the federal government and SEC resume normal operations before October 26, 2025.

The concurrent private placement would close with the IPO and depends on the public offering's completion, though the IPO does not require the private placement to proceed. MapLight noted it has not entered binding agreements with proposed private placement purchasers.

Morgan Stanley, Jefferies, Leerink Partners and Stifel serve as joint book-running managers for the offering, according to the company's press release.

You May Also Be Interested In

• Agility Robotics to go public via $2.5B SPAC merger
• MoonLake prices $200 million public offering at $20 per share
• SK hynix files for Nasdaq IPO under ticker symbol SKHY